The number of Covid-19 infections in the US surpassed 10.4 million, with over 59 thousand patients in hospitals. This is the highest number of hospitalizations since July, as number of new infections continues to surge across the country. Over the last 24 hours, the US reported around 120 thousand new cases.
Meanwhile US Food and Drug Administration (FDA) has authorized the emergency use of Eli Lilly’s (LLY.US) experimental COVID-19 antibody treatment bamlanivimab for non-hospitalized patients with mild-to-moderate symptoms. New treatment reduces the need for hospitalization or emergency room visits in COVID-19 patients at high risk of the disease worsening.
The number of Americans with COVID-19 currently hospitalized has surged around 73% over the past 30 days to at least 59,275. Source: The COVID Tracking Project.
Eli Lilly’s (LLY.US) stock jumped over 3% in pre-market and is currently testing strong resistance at $148.00 which is additionally strengthened by 200 SMA (red line). If the current sentiment prevails, the upward move could be extended to the next resistance at $157.44. On the other hand local support lies at $139.21. Source: xStation5
